AR012731A1 - Uso de un derivado de taxano para la preparacion de una composicion farmaceutica , uso de un agente mejorador de la biodicponibilidad de dicho derivado forma de dosificacion oral y conjunto afrmaceutico que lo comprende y metodo para formar a un agente activo biodisponible. - Google Patents
Uso de un derivado de taxano para la preparacion de una composicion farmaceutica , uso de un agente mejorador de la biodicponibilidad de dicho derivado forma de dosificacion oral y conjunto afrmaceutico que lo comprende y metodo para formar a un agente activo biodisponible.Info
- Publication number
- AR012731A1 AR012731A1 ARP980102356A ARP980102356A AR012731A1 AR 012731 A1 AR012731 A1 AR 012731A1 AR P980102356 A ARP980102356 A AR P980102356A AR P980102356 A ARP980102356 A AR P980102356A AR 012731 A1 AR012731 A1 AR 012731A1
- Authority
- AR
- Argentina
- Prior art keywords
- derivative
- taxane
- hours
- patient
- enhancing agent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Uso de un derivado de taxano para la preparacion de una composicion farmacéutica de utilidad en un método de tratamiento que incluye suadministracion en forma oral a un paciente humano que padece una dolencia que responde a este tipo de derivado, de tal manera que dicho derivado essuministrado en una cantidad efectiva a los efectos de tratar dicha dolencia. El derivado de taxano es paclitaxel; docetaxel; un derivado análogo oprofármaco de plactitaxel o doectaxel y dicho profármaco esplaclitaxel-2-MPM o docetaxel-2-MPM. La cantidad efectiva de placlitaxel oscila aproximadamenteentre 2 y 30 mg/kg de peso corporal del paciente o entre 20 y 1.000 mg/m2 de área de superficie corporal del paciente. Además, el método tiene por objetotornar biodisponible el derivado de taxano administrado por vía oral a pacientes humanos en un grado suficiente como para tratar enfermedades queresponden a los derivados de esta clase, comprendiendo la coadministracion por vía oral al paciente de una cantidad terapéutica efectiva del taxano junto conuna cantidad efectia de un agente mejorador de la biodisonibilidad seleccionado del grupo integrado por ciclosporina A a Z, (Me-Ile-4)-ciclosporina, dihidrociclosporina A, dichidro ciclosporina C y acetil ceclosporina A. El agente mejorador se administra aproximadamente entre 0,1 y 20 mg/kg con relacion alpeso corporal del paciente. Dicho agente mejorador es administrado ya sea: a) con una antelacion aproximada de 0,5 - 72 horas; b) con menos de 0,5 horas deanticipacion , junto, o dentro de las 0,5 horas posteriores; o c) ambas, con una antelacion aproximada de 0,5 - 72 horas y nuevamente con menos de 0,5 horasposteriores, a la administracion del taxano. El taxano yel agente mejorador son respectivamente administrados en formas de dosificacion independientes
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86351397A | 1997-05-27 | 1997-05-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR012731A1 true AR012731A1 (es) | 2000-11-08 |
Family
ID=25341241
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP980102356A AR012731A1 (es) | 1997-05-27 | 1998-05-21 | Uso de un derivado de taxano para la preparacion de una composicion farmaceutica , uso de un agente mejorador de la biodicponibilidad de dicho derivado forma de dosificacion oral y conjunto afrmaceutico que lo comprende y metodo para formar a un agente activo biodisponible. |
Country Status (23)
| Country | Link |
|---|---|
| EP (1) | EP0994706B1 (es) |
| JP (1) | JP2002500667A (es) |
| KR (1) | KR100615783B1 (es) |
| CN (2) | CN1550231A (es) |
| AR (1) | AR012731A1 (es) |
| AT (1) | ATE308365T1 (es) |
| AU (1) | AU7130098A (es) |
| BR (1) | BR9809694A (es) |
| CA (1) | CA2290446C (es) |
| CZ (1) | CZ9904244A3 (es) |
| DE (1) | DE69832173T2 (es) |
| DK (1) | DK0994706T3 (es) |
| ES (1) | ES2247690T3 (es) |
| HK (1) | HK1026637A1 (es) |
| HU (1) | HUP0003546A3 (es) |
| IL (2) | IL132992A0 (es) |
| NO (1) | NO995812L (es) |
| PL (1) | PL337064A1 (es) |
| RU (1) | RU2205005C2 (es) |
| SK (1) | SK157599A3 (es) |
| UA (1) | UA74767C2 (es) |
| WO (1) | WO1998053811A1 (es) |
| ZA (1) | ZA984268B (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6964946B1 (en) * | 1995-10-26 | 2005-11-15 | Baker Norton Pharmaceuticals, Inc. | Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same |
| CA2294606A1 (en) * | 1997-06-20 | 1998-12-30 | Baker Norton Pharmaceuticals, Inc. | Soluble prodrugs of paclitaxel |
| GB9718903D0 (en) | 1997-09-05 | 1997-11-12 | Glaxo Group Ltd | Method,compositions and kits for increasing the oral bioavailability of pharmaceutical agents |
| DE60030283T2 (de) | 1999-05-17 | 2007-09-20 | Cancer Research Ventures Ltd. | Zusammensetzungen zur erhöhung der bioverfügbarkeit von oral verabreichten pharmazeutischen verbindungen |
| SK5822002A3 (en) * | 1999-10-27 | 2003-01-09 | Baker Norton Pharma | Method and compositions for administering taxanes orally to human patients |
| KR20020013174A (ko) * | 2000-08-11 | 2002-02-20 | 민경윤 | 경구 흡수율이 낮은 약물의 흡수율을 증가시키기 위한경구용 조성물 |
| MXPA03006404A (es) * | 2001-01-18 | 2004-12-02 | Upjohn Co | Composiciones quimioterapeuticas de microemulsion de paclitaxel con biodisponibilidad oral mejorada. |
| US7115565B2 (en) | 2001-01-18 | 2006-10-03 | Pharmacia & Upjohn Company | Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability |
| UY27185A1 (es) * | 2001-02-28 | 2002-09-30 | Bristol Myers Squibb Co | Dosificación metronómica de taxanos |
| SI1372636T1 (sl) * | 2001-02-28 | 2006-12-31 | Bristol Myers Squibb Co | Metronomsko odmerjanje taksanov za inhibiranje tumorske rasti |
| US7063977B2 (en) | 2001-08-21 | 2006-06-20 | Bristol-Myers Squibb Company | Enzymatic resolution of t-butyl taxane derivatives |
| GB0523659D0 (en) * | 2005-11-21 | 2005-12-28 | Novartis Ag | Organic compounds |
| EP2438047B1 (en) * | 2009-06-02 | 2014-07-30 | Nikan Pharmaceuticals, LLC | Antagonism of human formyl peptide receptor for treatment of disease |
| BR112023018826A2 (pt) * | 2021-03-17 | 2024-03-12 | Dompe Farm Spa | Inibidores de c5ar1 para tratamento de reações de hipersensibilidade a taxanos |
| EP4059497A1 (en) * | 2021-03-17 | 2022-09-21 | Dompé farmaceutici S.p.a. | C5ar1 inhibitors for treating hypersensitivity reactions to taxanes |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5411947A (en) * | 1989-06-28 | 1995-05-02 | Vestar, Inc. | Method of converting a drug to an orally available form by covalently bonding a lipid to the drug |
| ATE139447T1 (de) * | 1990-12-18 | 1996-07-15 | Wellcome Found | Mittel zur verstaerkung der wirkung von antitumoralen mittel und zur widerstandsbekaempfung von vielfachdrogen |
| EP0569380B1 (en) * | 1991-01-11 | 1997-05-28 | Laboratoires Glaxo Sa | Acridine derivatives |
| US5567592A (en) * | 1994-02-02 | 1996-10-22 | Regents Of The University Of California | Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal |
| ATE176464T1 (de) * | 1994-07-26 | 1999-02-15 | Indena Spa | Semisynthetisch taxal derivate mit antitumor wirkung |
| TW354293B (en) * | 1995-06-06 | 1999-03-11 | Bristol Myers Squibb Co | Prodrugs of paclitaxel derivatives |
| EP0831870A4 (en) * | 1995-06-07 | 1998-09-16 | Avmax Inc | USE OF ESSENTIAL OILS TO INCREASE THE BIOAVAILABILITY OF ORAL PHARMACEUTICAL COMPOUNDS |
| US6245805B1 (en) * | 1995-10-26 | 2001-06-12 | Baker Norton Pharmaceuticals, Inc. | Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents |
| WO1997027855A1 (en) * | 1996-01-31 | 1997-08-07 | Bristol-Myers Squibb Company | A method of making pharmaceutically active taxanes orally bioavailable |
| AU3486297A (en) * | 1996-06-17 | 1998-01-07 | Eli Lilly And Company | Drug resistance and multidrug resistance modulators |
| GB9718903D0 (en) * | 1997-09-05 | 1997-11-12 | Glaxo Group Ltd | Method,compositions and kits for increasing the oral bioavailability of pharmaceutical agents |
| DE69931617T2 (de) * | 1998-04-01 | 2007-05-24 | Jagotec Ag | Taxan-mikroemulsionen |
-
1998
- 1998-04-22 KR KR1019997011000A patent/KR100615783B1/ko not_active IP Right Cessation
- 1998-04-22 CN CNA2004100304785A patent/CN1550231A/zh active Pending
- 1998-04-22 ES ES98918361T patent/ES2247690T3/es not_active Expired - Lifetime
- 1998-04-22 CN CN98806440A patent/CN1261275A/zh active Pending
- 1998-04-22 AT AT98918361T patent/ATE308365T1/de not_active IP Right Cessation
- 1998-04-22 AU AU71300/98A patent/AU7130098A/en not_active Abandoned
- 1998-04-22 BR BR9809694-0A patent/BR9809694A/pt not_active IP Right Cessation
- 1998-04-22 SK SK1575-99A patent/SK157599A3/sk unknown
- 1998-04-22 JP JP50066399A patent/JP2002500667A/ja active Pending
- 1998-04-22 HU HU0003546A patent/HUP0003546A3/hu unknown
- 1998-04-22 CA CA002290446A patent/CA2290446C/en not_active Expired - Fee Related
- 1998-04-22 DK DK98918361T patent/DK0994706T3/da active
- 1998-04-22 PL PL98337064A patent/PL337064A1/xx unknown
- 1998-04-22 RU RU99128033/14A patent/RU2205005C2/ru not_active IP Right Cessation
- 1998-04-22 EP EP98918361A patent/EP0994706B1/en not_active Expired - Lifetime
- 1998-04-22 DE DE69832173T patent/DE69832173T2/de not_active Expired - Fee Related
- 1998-04-22 IL IL13299298A patent/IL132992A0/xx active IP Right Grant
- 1998-04-22 WO PCT/US1998/007776 patent/WO1998053811A1/en active IP Right Grant
- 1998-04-22 UA UA99116450A patent/UA74767C2/uk unknown
- 1998-04-22 CZ CZ19994244A patent/CZ9904244A3/cs unknown
- 1998-05-20 ZA ZA984268A patent/ZA984268B/xx unknown
- 1998-05-21 AR ARP980102356A patent/AR012731A1/es unknown
-
1999
- 1999-11-17 IL IL132992A patent/IL132992A/en not_active IP Right Cessation
- 1999-11-26 NO NO995812A patent/NO995812L/no not_active Application Discontinuation
-
2000
- 2000-09-20 HK HK00105943A patent/HK1026637A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| DE69832173T2 (de) | 2006-08-03 |
| CZ9904244A3 (cs) | 2001-10-17 |
| ATE308365T1 (de) | 2005-11-15 |
| HK1026637A1 (en) | 2000-12-22 |
| EP0994706A4 (en) | 2001-05-16 |
| WO1998053811A1 (en) | 1998-12-03 |
| EP0994706A1 (en) | 2000-04-26 |
| ES2247690T3 (es) | 2006-03-01 |
| EP0994706B1 (en) | 2005-11-02 |
| CN1550231A (zh) | 2004-12-01 |
| NO995812L (no) | 2000-01-25 |
| SK157599A3 (en) | 2002-10-08 |
| IL132992A (en) | 2006-08-20 |
| CA2290446C (en) | 2008-01-29 |
| ZA984268B (en) | 1999-06-23 |
| KR20010013025A (ko) | 2001-02-26 |
| CA2290446A1 (en) | 1998-12-03 |
| UA74767C2 (en) | 2006-02-15 |
| BR9809694A (pt) | 2000-10-03 |
| HUP0003546A2 (hu) | 2002-11-28 |
| NO995812D0 (no) | 1999-11-26 |
| AU7130098A (en) | 1998-12-30 |
| JP2002500667A (ja) | 2002-01-08 |
| CN1261275A (zh) | 2000-07-26 |
| HUP0003546A3 (en) | 2002-12-28 |
| DK0994706T3 (da) | 2006-03-06 |
| PL337064A1 (en) | 2000-07-31 |
| KR100615783B1 (ko) | 2006-08-25 |
| IL132992A0 (en) | 2001-03-19 |
| RU2205005C2 (ru) | 2003-05-27 |
| DE69832173D1 (de) | 2005-12-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR012731A1 (es) | Uso de un derivado de taxano para la preparacion de una composicion farmaceutica , uso de un agente mejorador de la biodicponibilidad de dicho derivado forma de dosificacion oral y conjunto afrmaceutico que lo comprende y metodo para formar a un agente activo biodisponible. | |
| BR0009016A (pt) | Composição de apomorfina e sildenafil | |
| RU2012106620A (ru) | Комбинации и способы введения терапевтических средств и комбинированной терапии | |
| JP2006514092A5 (es) | ||
| ES2038669T3 (es) | Formulacion farmaceutica. | |
| HUP0300027A2 (en) | Nucleoside analogs with carboxamidine modified monocyclic base and process for their use | |
| AR033953A1 (es) | Una forma de droga libre en particulas de un compuesto de beta-carbolina , su composicion farmaceutica, metodo de tratamiento de la disfuncion sexual , metodo para fabricar dicha forma del compuesto y uso de las particulas | |
| JP2002528502A5 (es) | ||
| CO5251425A1 (es) | Metodo y composiciones para administrar taxanos oralmente a pacientes humanos | |
| JP2002523437A5 (es) | ||
| RU2007119545A (ru) | Пегилированный липосомальный доксорубицин в комбинации с эктеинасцидином 743 (ecteinescidin 743) | |
| JP2003514025A5 (es) | ||
| JP2008517991A5 (es) | ||
| TR200200401T2 (tr) | PEG-IFN-a ile birlikte mikofenolat mofetil | |
| RU2005131578A (ru) | Аплидин для лечения множественной миеломы | |
| CA2516458A1 (en) | Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis | |
| HUP0204324A2 (en) | Use of fsh for preparation of pharmaceutical composition suitable for treating infertility | |
| AR025549A1 (es) | Mofetil micofelonato en asociacion con peg-ifn-alfa | |
| ATE91890T1 (de) | Herstellung eines arzneimittels gegen arthritis und rheumatismus. | |
| BR9917605A (pt) | Composição substituta de plasma | |
| ES2339263T3 (es) | Uso de trifluoroacetato de calcio par ala preparacion de medicamentos con efecto antiangiogenico. | |
| ES2211374T1 (es) | Dosificacion metronomica de taxanos para inhibir el crecimiento tumoral. | |
| WO2000043014A3 (en) | Beta-d-2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine for use in the treatment of hiv infections | |
| ES2235415T3 (es) | Composiciones antivirales que comprenden yohimbina como principio activo. | |
| AR109456A2 (es) | Uso de et743 para la preparación de un medicamento para el tratamiento de un paciente humano afectado por cáncer mediante terapia de combinación |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |